Dyne Therapeutics, Inc.

Symbol: DYN

NASDAQ

25.95

USD

Market price today

  • -8.1705

    P/E Ratio

  • -0.0768

    PEG Ratio

  • 2.10B

    MRK Cap

  • 0.00%

    DIV Yield

Dyne Therapeutics, Inc. (DYN) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.51%

Operating Profit Margin

-70.18%

Net Profit Margin

-67.95%

Return on Assets

-0.49%

Return on Equity

-1.11%

Return on Capital Employed

-0.53%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. John G. Cox M.B.A.
Full-time employees:143
City:Waltham
Address:1560 Trapelo Road
IPO:2020-09-17
CIK:0001818794

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

General Outlook

When we look at how much money they make before expenses, they keep 0.515% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -70.183%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -67.951%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.493% return, is a testament to Dyne Therapeutics, Inc.'s adeptness in optimizing resource deployment. Dyne Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.109%. Furthermore, the proficiency of Dyne Therapeutics, Inc. in capital utilization is underscored by a remarkable -0.532% return on capital employed.

Stock Prices

Dyne Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $27.29, while its low point bottomed out at $25.21. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Dyne Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing DYN liquidity ratios reveals its financial health of the firm. The current ratio of 2182.81% gauges short-term asset coverage for liabilities. The quick ratio (2028.11%) assesses immediate liquidity, while the cash ratio (1216.45%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio2182.81%
Quick Ratio2028.11%
Cash Ratio1216.45%

Profitability Ratios

DYN profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -6795.12% underscores its earnings before tax deductions. The effective tax rate stands at 0.51%, revealing its tax efficiency. The net income per EBT, 100.00%, and the EBT per EBIT, 96.82%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -7018.32%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-6795.12%
Effective Tax Rate0.51%
Net Income per EBT100.00%
EBT per EBIT96.82%
EBIT per Revenue-7018.32%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 21.83, it details the span from stock purchase to revenue. The 20 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding2028
Days of Payables Outstanding1433
Cash Conversion Cycle-1433
Payables Turnover0.25
Fixed Asset Turnover0.12
Asset Turnover0.01

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -2.71, and free cash flow per share, -2.72, depict cash generation on a per-share basis. The cash per share value, 5.60, showcases liquidity position. Lastly, the operating cash flow sales ratio, -58.02, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-2.71
Free Cash Flow per Share-2.72
Cash per Share5.60
Operating Cash Flow Sales Ratio-58.02
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-8.26
Short Term Coverage Ratio-46.21
Capital Expenditure Coverage Ratio-318.53
Dividend Paid and Capex Coverage Ratio-318.53

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 5.10%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.06, we discern the balance between debt and equity financing. The long-term debt to capitalization, 4.37%, and total debt to capitalization, 5.27%, ratios shed light on its capital structure. An interest coverage of -157.40 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio5.10%
Debt Equity Ratio0.06
Long Term Debt to Capitalization4.37%
Total Debt to Capitalization5.27%
Interest Coverage-157.40
Cash Flow to Debt Ratio-8.26
Company Equity Multiplier1.09

Per Share Data

Net income per share, -3.95, reflects the portion of profit attributed to each share. The book value per share, 1.53, represents the net asset value distributed per share, while the tangible book value per share, 1.53, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-3.95
Book Value Per Share1.53
Tangible Book Value Per Share1.53
Shareholders Equity Per Share1.53
Interest Debt Per Share0.46
Capex Per Share-0.01

Growth Ratios

EBIT growth, -41.65%, and operating income growth, -41.65%, offer insights into operational profitability progression. The net income growth, -42.79%, showcases bottom-line expansion, and the EPS growth, -24.21%, measures the growth in earnings per share.

cards.indicatorcards.value
Gross Profit Growth26.43%
EBIT Growth-41.65%
Operating Income Growth-41.65%
Net Income Growth-42.79%
EPS Growth-24.21%
EPS Diluted Growth-24.21%
Weighted Average Shares Growth14.83%
Weighted Average Shares Diluted Growth14.83%
Operating Cash Flow Growth-22.46%
Free Cash Flow Growth-20.53%
10-Year Revenue Growth per Share-100.00%
10-Year Operating CF Growth per Share-280.15%
5-Year Operating CF Growth per Share-681.70%
3-Year Operating CF Growth per Share2.42%
10-Year Net Income Growth per Share-11.04%
5-Year Net Income Growth per Share-748.38%
3-Year Net Income Growth per Share3.11%
10-Year Shareholders Equity Growth per Share-93.08%
5-Year Shareholders Equity Growth per Share423.69%
3-Year Shareholders Equity Growth per Share-93.57%
Asset Growth-46.11%
Book Value per Share Growth-68.50%
Debt Growth-10.06%
R&D Expense Growth47.63%
SGA Expenses Growth2.61%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 699,584,218.3, captures the company's total value, considering both debt and equity. Income quality, 0.80, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value699,584,218.3
Income Quality0.80
Capex to Operating Cash Flow0.39%
Capex to Depreciation-29.62%
Graham Number11.66
Return on Tangible Assets-142.92%
Graham Net Net0.83
Working Capital78,280,000
Tangible Asset Value91,292,000
Net Current Asset Value55,585,000
Average Payables14,097,500
Days Payables Outstanding3402
ROIC-204.00%
ROE-2.58%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 4.40, and the price to book ratio, 4.40, reflect the market's valuation relative to the company's book value. The price to sales ratio, 555.62, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -9.55, and price to operating cash flows, -9.57, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio4.40
Price to Book Ratio4.40
Price to Sales Ratio555.62
Price Cash Flow Ratio-9.57
Price Earnings to Growth Ratio-0.08
Enterprise Value Multiple-8.89
Price Fair Value4.40
Price to Operating Cash Flow Ratio-9.57
Price to Free Cash Flows Ratio-9.55
Price to Tangible Book Ratio8.70
Enterprise Value Over EBITDA-2.92
EV to Operating Cash Flow-3.72
Earnings Yield-29.72%
Free Cash Flow Yield-23.80%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Dyne Therapeutics, Inc. (DYN) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -8.171 in 2024.

What is the ticker symbol of Dyne Therapeutics, Inc. stock?

The ticker symbol of Dyne Therapeutics, Inc. stock is DYN.

What is company IPO date?

IPO date of Dyne Therapeutics, Inc. is 2020-09-17.

What is company current share price?

Current share price is 25.950 USD.

What is stock market cap today?

The market cap of stock today is 2104703295.000.

What is PEG ratio in 2024?

The current -0.077 is -0.077 in 2024.

What is the number of employees in 2024?

In 2024 the company has 143.